xtensive experimental and clinical evidence accumulated over the past several years indicates that the infarcted heart can be repaired by endogenous as well as exogenous stem/progenitor cells. Experimental studies from several laboratories have reported that bone marrowderived endothelial progenitor cells (EPCs) are mobilized after acute myocardial infarction (MI), home to the infarcted myocardium, and improve left ventricular (LV) perfusion and function. 1 Although EPCs have been shown to differentiate into a cardiomyocytic phenotype in vitro, EPC-induced beneficial effects appear to stem primarily from myocardial neovascularization. In an effort to enhance EPC-mediated cardiovascular reparative benefits, current studies are focused on the molecular mechanistic aspects of this phenomenon and on the modulation of EPC kinetics.
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Clinical evidence also supports an important role for EPCs in atherosclerotic cardiovascular disease. Lower numbers of colony-forming circulating EPCs are associated with an increased Framingham risk factor score and endothelial dysfunction, 2 and the number of circulating EPCs predicts the severity of coronary artery disease. 3 These observations underscore the fact that EPCs participate not only in tissue repair after injury but also in the maintenance of endothelial integrity and function. After a stressful event such as acute MI or myocardial ischemia, additional EPCs are mobilized from the bone marrow, home to the injured tissue, and participate in neovascularization. Taken together, these considerations suggest that enhanced cardiac repair after MI may potentially be achieved by augmenting mobilization, myocardial homing, and functionality of EPCs. Elucidation of the signaling mechanisms involved in these processes is therefore important to the development of therapeutic strategies for cardiac repair.
Although the role of EPCs in cardiac repair is a relatively new field of investigation, the influence of estrogen on cardiovascular health has been studied for decades. Estrogen exerts multifaceted effects on the heart and blood vessels via genomic and nongenomic actions. The genomic action is slower in onset and is mediated via 2 estrogen receptors (ERs), ER␣ and ER␤. Both ER␣ and ER␤ are expressed in endothelium, vascular smooth muscle cells, and cardiomyocytes. ERs are expressed primarily in the cytosol, and upon binding to estrogen (which diffuses into the cell), they translocate to the nucleus and regulate transcription of a number of genes. The tissue distribution of the 2 ERs varies considerably, and the effects of ER␤-mediated signaling remain incompletely understood. Recent evidence indicates that estrogen augments production of EPCs 4 and attenuates their senescence. 5 In this issue of Circulation, Hamada and colleagues 6 report a number of important new observations on the role of specific ERs in EPC biology and in cardiac repair. This report is a follow-up to a previous study 7 in which these authors demonstrated that estradiol exerts cardioprotective effects in the setting of acute MI in mice via augmented mobilization and homing of EPCs and enhanced angiogenesis, resulting in improved cardiac function. The present findings identify a differential role of the 2 ERs in these phenomena. In vitro, the effects of estradiol on migration, proliferation, and tube formation by EPCs were severely impaired in EPCs from ER␣ Ϫ/Ϫ mice, whereas they were moderately attenuated in EPCs from ER␤ Ϫ/Ϫ mice. In vivo, both the mobilization of endogenous Sca-1 ϩ /Flk-1 ϩ EPCs after MI and the homing of exogenous EPCs to the infarct border zone after estradiol treatment were significantly greater in wild-type (WT) mice than those observed in WT recipients of ER␣ Ϫ/Ϫ or ER␤ Ϫ/Ϫ marrow. Consistent with these findings, WT recipients of ER␣ Ϫ/Ϫ or ER␤ Ϫ/Ϫ marrow exhibited lower capillary density in the border zone of the infarct and worse LV function. The absence of ER␣ had a consistently greater impact on the end points of these experiments than did the absence of ER␤. Furthermore, EPCs were found to express greater amounts of ER␣ mRNA and bind estradiol in a predominantly ER␣dependent manner. Interestingly, the expression of vascular endothelial growth factor in EPCs was significantly downregulated in the absence of ER␣. Taken together, the results of this elegant study indicate that, although both ERs participate in estradiol-induced cardiac repair via EPC mobilization, myocardial homing, and angiogenesis, signaling via ER␣ is considerably more important in mediating these processes.
At present, the specific roles of ER␣ and ER␤ in the cardiovascular system remain incompletely understood. Estradiol-induced reendothelialization in a mouse carotid artery injury model is ER␣ dependent. 8 Because EPCs
The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association. contribute to reendothelialization after arterial injury, expression of ER␣ on EPCs may be critical in this setting. In humans, women homozygous for the T allele of the PvuII polymorphism of ER␣ are at greater risk of in-stent restenosis after coronary angioplasty. 9 Furthermore, compared with the CT and TT genotypes, the CC genotype of ER␣ is associated with an increased incidence of cardiovascular disease, including MI. 10 Both observations 9,10 support the primacy of ER␣ in endothelial homeostasis. On the other hand, increased endothelial expression of ER␤ but not ER␣ has been reported in a rat model of aortic balloon injury, 11 and expression of ER␤ has been found to correlate with coronary calcification and atherosclerosis in pre-as well as postmenopausal women. 12 In addition, after coronary artery ligation, ER␤ Ϫ/Ϫ mice have been reported to exhibit increased mortality and more severe heart failure despite similar infarct size compared with WT mice 13 ; however, ER␣ Ϫ/Ϫ mice were not examined. Thus, current evidence suggests that both ERs play important and possibly somewhat overlapping roles in the cardiovascular system. The findings of Hamada et al, 6 which indicate greater expression of ER␣ in EPCs and a greater role of ER␣ in EPC-mediated repair of acute MI, are significant because they focus attention on this specific receptor. These results will likely stimulate further research into the relative contributions of ER␣ vis-à-vis ER␤ to disease processes in which EPCs may potentially play a critical role, such as the genesis, progression, and repair of atherosclerotic lesions.
The reduction in the size of the scar observed in the present study after estradiol treatment is intriguing. Because cardiomyocytes express both ER␣ and ER␤, one could interpret these findings as evidence that estradiol exerted a direct cardioprotective effect (perhaps mediated by activation of the PI3-kinase-Akt pathway 14 ) and limited the initial size of the infarct, resulting in subsequent smaller scars. This hypothesis, however, is not plausible because the authors used a model of permanent coronary occlusion. Myocytes rendered ischemic by a coronary occlusion cannot tolerate sustained severe ischemia; in the absence of reperfusion, no therapeutic intervention can salvage them, and these cells will die regardless of the treatment applied. Indeed, most previous studies showing that estradiol limits infarct size have used models of temporary coronary occlusion followed by reperfusion [15] [16] [17] ; studies in models of permanent coronary ligation failed to show any infarct-sparing effect of estradiol. 18, 19 It appears far more likely that the reduced size of the scar observed by Hamada et al 6 in estradiol-treated mice was due to attenuation of LV remodeling (producing less stretching of the scar), alleviation of the ongoing apoptosis of surviving myocytes after the acute phase of the infarct, regeneration of myocytes, and/or other as yet unknown processes. The mechanism that underlies the robust beneficial effects of estradiol on the size of the scar merits further investigation, for these studies may not only unravel novel aspects of ER biology but also illuminate new mechanisms whereby post-MI remodeling can be alleviated.
Another important issue that needs to be investigated is whether EPCs are the only bone marrow cell type that is modulated by ERs, or whether estrogen affects cardiac repair more broadly by regulating other bone marrow cells as well.
The multifaceted effects of estrogen on bone marrow have been known for many years, and several types of bone marrow cells have been found to express ERs. 20 In addition, besides EPCs, other bone marrow cells have been shown to express markers of endothelial lineage and, with appropriate stimuli and culture conditions, to differentiate into an endothelial phenotype. 1 The role of ERs in modulating these potential candidates for neovascularization remains largely unknown. Furthermore, "circulating progenitors" with endothelial differentiation capability represent a phenotypically and functionally heterogeneous population. 1, 21 Hamada et al 6 have recently shown that estradiol mobilizes EPCs via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9. 7 Elucidation of the effects of estradiol on other bone marrow stem/progenitors could potentially identify other pathways by which estradiol affords reparative benefits in the cardiovascular system.
The findings of Hamada et al 6 have significant clinical implications. First, ER␤ has been identified as the predominant ER isoform both in coronary intima and in coronary media in women. 12 In view of the results of the population studies mentioned above, it seems important to investigate whether the number of circulating EPCs in subjects with ER␣ variants correlates with the incidence of adverse cardiovascular events. If the findings of Hamada et al 6 with regard to ER subtype expression in mouse EPCs hold true in humans, in vitro analysis of ER expression in EPCs may identify patients at greater risk of cardiovascular events. Second, given the beneficial effects of estradiol-induced mobilization of bone marrow cells on cardiac function, should estradiol be administered after acute MI, especially in postmenopausal women? The answer to this question appears to be rather complicated. Hormone replacement therapy (HRT) in postmenopausal women was the accepted standard of care for many years until a randomized clinical trial showed that HRT actually increased the risk of cardiac events. 22 Several other studies have since reported either no benefit or deleterious effects of HRT on cardiovascular outcomes. In the specific setting of acute MI, however, there is evidence that HRT may improve mortality. 23 The present results support this concept and suggest that, after acute MI, ER-specific therapies may be advantageous. A better understanding of estrogen signaling via specific ERs and future clinical studies with estrogen therapy alone may conceivably produce a therapeutic paradigm shift. Third, a growing body of evidence suggests that estrogen favorably modulates endothelial function after coronary stenting. 24 If this beneficial effect is influenced by the ER expression pattern on human EPCs, selective ER modulators may be used to improve outcomes after stenting. Finally, premenopausal women appear to be protected from cardiovascular events. Because long-term estrogen exposure upregulates ER␣ and downregulates ER␤ expression in endothelial cells, 25 it will be interesting to determine whether gender-dependent differences in ER expression on EPCs (ie, greater expression of ER␣ in women versus men) contribute to estrogen-related protection from cardiovascular events in premenopausal women.
In summary, despite numerous phenomenological reports, the role of circulating EPCs in endothelial and cardiac repair remains incompletely understood. The study by Hamada and colleagues 6 is important because it reveals that, after MI, mobilization of EPCs, myocardial homing of these cells, and subsequent EPC-mediated cardiac repair are differentially regulated by specific ERs. These findings have clinical implications for understanding the relative roles of the 2 ERs in cardiovascular homeostasis and exploring the potential role of selective ER modulators in cardiac as well as vascular repair. Further studies will be necessary to investigate whether the ER-mediated beneficial effects of estradiol on postinfarction remodeling and function also involve other bone marrow cells, to decipher the molecular events whereby estradiol mobilizes EPCs, and to determine the mechanism whereby these EPCs home to the infarcted myocardium in an ER-dependent fashion.
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